ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In the global, phase 3, open‐label ASCEMBL study in patients with CML in chronic phase (CML‐CP) pretreated with = 2 tyrosine kinase inhibitors (TKIs), asciminib (40 mg twice‐daily) demonstrated statistically significant superiority over the ATP‐competitive TKI bosutinib (500 mg once daily) for the primary endpoint of major molecular response (MMR; BCR‐ABL1 transcript levels on the international scale [BCR‐ABL1IS] = 0.1%) at week 24.